The malaria vaccine under development by GSK and the PATH initiative only protects about one in three babies, though some researchers say those odds are better than nothing.
Many vaccines are on the market for various serogroups of meningococcal disease, but a solution to provide broad protection against MenB remains elusive.
Are states with less rigorous rules about which children can claim an exception from vaccination in kindergarten putting communities at higher risk of childhood disease?
Gayatri Vedantam and Glenn S. Tillotson | May 1, 2011 | 10+ min read
Clostridium difficile is evolving more robust toxicity, repeatedly attacking its victims, and driving the search for alternative therapies to fight the infection.